Trials — SGO 2026¶
The primary artifact of this vault: one Markdown file per trial / readout. SGO 2026 is a clinical-readout meeting, so the unit of analysis is the trial — not the speaker, not the surgical platform, not the company.
Status: Scaffold (post-meeting) — ready for retrospective bulk extraction. Meeting closed one month ago (Apr 10–13, 2026). All abstract embargoes lifted; the master index below is finalized with verified readouts from Gynecologic Oncology abstracts, simultaneous Lancet / NEJM / JCO publications, SGO Meeting News daily coverage, and OncLive / Targeted Oncology / OncoDaily trade-press recaps. Per-trial pages will be filled in mechanically — the shape, master index, and source URLs are pre-wired here.
Per-trial template¶
Each trial file (e.g., rosella.md) follows this schema. Copy and fill:
# <Trial acronym / name> — <Drug regimen, indication, line>
> **Abstract:** <abstract #, e.g., LBA1> · **Session:** <Plenary I / II / III / IV / V, date, time AST, hall> · **Simultaneous publication:** <Lancet / NEJM / JCO / Gyn Onc DOI>
## At a glance
- **Sponsor:** <pharma / cooperative group(s) — often multi-group: GOG / NRG / ENGOT / APGOT / LACOG / ANZGOG>
- **PI / presenter:** <name, institution>
- **NCT ID:** <NCTxxxxxxxx>
- **Phase:** <1 / 1-2 / 2 / 2-3 / 3>
- **Design:** <arms, randomization, blinding, biomarker selection>
- **N:** <enrolled / analyzed>
- **Primary endpoint(s):** <PFS / OS / ORR / DOR / pCR>
- **Comparator:** <SOC / placebo / active comparator>
- **Indication:** <tumor type, subtype, biomarker — e.g., FRα+ PSOC, dMMR/MSI-H endometrial, locally advanced cervical>
- **Line:** <neoadjuvant / adjuvant / 1L / 2L / 3L+ / maintenance>
## Headline result
<One paragraph. Numbers + HR + p-value. Cite simultaneous publication if applicable
(e.g., "Lancet 2026 Apr 11 — DOI:10.1016/S0140-6736(26)00462-9").>
## Mechanism / class
<Drug class, target, prior approvals if any. Cross-link to related AACR mechanism sessions
(B7-H4, CDH6, FRα, B7-H3, TROP2, glucocorticoid receptor antagonism, etc.).>
## Discussant / moderator takeaway
<Named Plenary moderator + key framing. SGO Plenary moderators are typically NCCN
panel members — their framing translates directly into guideline updates.>
## Practice-changing?
<Yes / no / pending, with rationale: NCCN guideline implications, FDA filing path,
unmet need, prior SOC. ROSELLA is a fast-cycle example — Mar 2026 FDA approval
preceded the SGO presentation.>
## Cross-links
- **AACR 2026:** <related plenary / session / poster on the target class, e.g., B7-H4, CDH6>
- **AACR prior years:** <preclinical mechanism work — relacorilant GR antagonism, MIRV FRα biology>
- **Other SGO 2026 trials:** <same disease / same class>
- **ASCO 2026 forward link:** <expected May/Jun sequel — OS update, subgroup analysis, biomarker correlates>
- **ESMO 2026 forward link:** <expected Oct sequel — European subgroup, mature follow-up>
- **JPM 2026:** <sponsor investor presentation Jan 12–15>
- **Tools:** <if a biomarker / ctDNA / FRα IHC / B7-H4 IHC method anchored the trial>
## Sources
- *Gynecologic Oncology* abstract: <URL or DOI>
- Simultaneous publication (*Lancet* / *NEJM* / *JCO*): <URL or DOI>
- SGO Meeting News daily-coverage: <URL>
- Company press release: <URL>
- Trade-press recap: <OncLive / Targeted Oncology / OncoDaily / CancerNetwork URL>
- ClinicalTrials.gov: <NCT URL>
Master trial index¶
Verified post-meeting (Apr 10–13, 2026). Numbers below are on-record from the SGO abstracts + simultaneous publications + post-meeting trade-press recaps. Result column is final-data, not pre-embargo.
Ovarian cancer¶
| Trial | Sponsor | Indication | Phase | Endpoint | Result | Moderator / Plenary | Practice-changing? |
|---|---|---|---|---|---|---|---|
| ROSELLA (LBA, Plenary I) | Corcept · GOG-3073 / ENGOT-ov72 / APGOT-Ov10 / LACOG-0223 / ANZGOG-2221 | Platinum-resistant epithelial ovarian (post-bev) | 3 | OS + PFS (dual primary) | mOS 16.0 vs 11.9 mo, HR 0.65 (95% CI 0.51–0.83), p=0.0004; mPFS HR 0.70, p=0.0076; simultaneous Lancet publication | Plenary I, Apr 10 | Yes — Lifyorli (relacorilant) FDA-approved Mar 2026; first GR-antagonist class win in solid tumor |
| KEYNOTE-B96 (Plenary I encore) | Merck · ENGOT-ov65 | Platinum-resistant recurrent ovarian | 3 | PFS | PFS positive (per FDA approval Feb 2026); pembro + paclitaxel ± bev | Plenary I, Apr 10 | Yes — FDA-approved 1Q26 |
| NRG-GY019 (Plenary I) | NRG | Low-grade serous ovarian, frontline | 3 | PFS (non-inferiority) | Letrozole alone failed non-inferiority vs paclitaxel/carboplatin + letrozole — chemo retained in LGSOC SOC | Plenary I, Apr 10 (presenter: Amanda Fader, MD) | Yes (negative) — preserves chemo backbone in LGSOC |
| Mirvetuximab + carboplatin → MIRV maintenance (LBA) | AbbVie · IMGN853-0420 | Platinum-sensitive recurrent ovarian, FRα+ | 2 | ORR maintenance | ORR 68% in maintenance phase; 63.9% in PARPi-pretreated subgroup; 81% continued to MIRV monotherapy maintenance | Apr 12 | Supports moving ELAHERE earlier into PSOC; AbbVie life-cycle |
| REJOICE-Ovarian01 | Daiichi Sankyo | Platinum-resistant high-grade serous/endometrioid ovarian | 2/3 | ORR | ORR 50.5% overall; CDH6 ADC first clinical efficacy at scale | Apr 11 | Pivotal Ph3 expansion design; first CDH6-targeted class data |
| RAMP-201 follow-up | Verastem | Low-grade serous ovarian (recurrent) | 2 | DOR / PFS | DOR 31 mo; PFS 12.9 mo overall, 19.6 mo in KRAS-mut subgroup | Apr 10 | Confirms avutometinib + defactinib durability in KRAS-mut LGSOC |
| GLORIOSA / TroFuse-022 / RAINFOL-04 | Multiple sponsors | Platinum-sensitive recurrent ovarian | 3 | PFS / OS | Updates from ADC-maintenance Ph3 designs (mirvetuximab + bev, sac-tirumotecan, etc.) | Apr 11 | Maintenance ADC class — defining future SOC |
| BNT-324 (Phase 1/2) | BioNTech | Platinum-sensitive + platinum-resistant ovarian | 1/2 | ORR | Anti-B7-H3 ADC active in both settings | Apr 11 | Early signal; B7-H3 class entry |
| BEHOLD-1 | TBD sponsor | Platinum-resistant recurrent ovarian | 1/2 | ORR | ORR 62% in platinum-resistant | Apr 11 | Early-phase ADC; pivotal-design-defining |
Endometrial cancer¶
| Trial | Sponsor | Indication | Phase | Endpoint | Result | Moderator / Plenary | Practice-changing? |
|---|---|---|---|---|---|---|---|
| RUBY 4-year OS (Plenary III) | GSK · ENGOT-EN6-NSGO/GOG-3031 | 1L advanced/recurrent endometrial (all-comer, with dMMR primary) | 3 | OS (mature update) | dMMR/MSI-H: HR 0.32 (95% CI 0.17–0.63) — 68% mortality reduction; ~73% 4-yr OS; MMRp HR 0.79, 7-mo median OS gain | Plenary III, Apr 12 | Yes (confirmatory) — dostarlimab + chemo 1L SOC reinforced |
| Puxitatug samrotecan BLUESTAR (LBA, Ph1/2a) | AstraZeneca · AZD8205 | Advanced/metastatic endometrial cancer | 1/2a | ORR / PFS | ORR 34.6% @ 2.0 mg/kg, 38.5% @ 2.4 mg/kg; 12-wk DCR 80.8% / 84.6%; mPFS 7.0 mo | Apr 12 (presenter: Stephanie Gaillard, MD, Johns Hopkins) | First-in-human B7-H4 ADC clinical efficacy data |
| D-RT | GSK | Adjuvant stage III-IVA dMMR endometrial (no residual) | 2 | DFS | Chemo-free dostarlimab + RT — feasibility + efficacy in dMMR adjuvant | Apr 12 | Pilot for chemo-free adjuvant in dMMR |
| GOG-3039 | GOG | Advanced/recurrent HR+ endometrioid endometrial | 2 | PFS / ORR | 6-mo PFS 57%; ORR 39% with abemaciclib + letrozole | Apr 12 | Defines CDK4/6 + AI signal in HR+ endometrial |
| Destiny-Endometrial01 / 02 / TroFuse-033 | Daiichi/AZ, Merck/Kelun | Adjuvant / 1L endometrial ADC | 3 | PFS | Ph3 ADC designs in adjuvant + 1L | Apr 12 | Defines next-line endometrial SOC |
| BEHOLD-01 | TBD sponsor | Recurrent endometrial | 1/2 | ORR | ORR 67% | Apr 12 | Early-phase signal |
Cervical cancer¶
| Trial | Sponsor | Indication | Phase | Endpoint | Result | Moderator / Plenary | Practice-changing? |
|---|---|---|---|---|---|---|---|
| KEYNOTE-A18 mature OS | Merck · ENGOT-cx11 / GOG-3047 | Locally advanced cervical (high-risk, stage IB–IVA) | 3 | OS (long-term FU) | OS HR 0.73 (95% CI 0.57–0.94); 36-mo OS 81.8% vs 74.4%; 48-mo OS 75.4% vs 70.2%; no new safety signals | Apr 13 | Yes — pembro + CCRT 1L SOC for high-risk LACC, durable benefit |
| InnovaTV 205 Arm H | Pfizer/Seagen · Genmab | 1L recurrent/metastatic cervical | 2 | ORR / DOR | ORR 66%; mDOR 13 mo with tisotumab vedotin + carboplatin + pembrolizumab ± bevacizumab | Apr 13 | TV + chemo-IO 1L expansion |
| TroFuse-036 | Merck/Kelun | Cervical maintenance post-CCRT | 2 | PFS | Sacituzumab tirumotecan + pembro ± bev; novel maintenance strategy | Apr 13 | Defines post-CCRT maintenance design space |
| IBI130 (Phase 1/2) | Innovent | Recurrent/metastatic cervical | 1/2 | ORR | ORR 53%; manageable safety — anti-TROP2 ADC | Apr 13 | China-origin TROP2 ADC entry in cervical |
Surgical innovation + rare tumors (Day 4 Plenary V)¶
| Topic | Setting | Headline |
|---|---|---|
| Sentinel lymph node mapping in early-stage endometrial | Surgical | Updated SLN-mapping algorithm performance + ultra-staging |
| Robotic platforms in cervical surgery | Surgical | Long-term outcomes post-LACC trial reassessment |
| Fertility-sparing in early cervical | Surgical | Trachelectomy and conization outcomes |
| Uterine leiomyosarcoma combination Ph2 | Sarcoma | Novel combination Ph2 data |
Cross-cutting themes (for program-notes.md)¶
To synthesize across the trial list:
- ADC era arrives in gyn-onc. Six distinct ADC targets with 2026 clinical efficacy data: FRα (mirvetuximab — moving earlier into PSOC), CDH6 (raludotatug deruxtecan — first signal), B7-H4 (puxitatug samrotecan AZD8205 — first-in-human), B7-H3 (BNT-324), TROP2 (sacituzumab tirumotecan, IBI130), tissue factor (tisotumab vedotin). This is the AACR ADC linker-chemistry-payload mechanism story landing in the clinic.
- Glucocorticoid receptor antagonism is a class. ROSELLA's Lifyorli win (relacorilant) is the first GR-antagonist solid-tumor Phase 3 win — a new class with read-through to cortisol-axis biology across hormone-receptor-modulated cancers.
- Chemo-immunotherapy 1L is now SOC across all three gyn cancers. RUBY (endometrial dostarlimab), KEYNOTE-A18 (cervical pembro + CCRT), KEYNOTE-B96 (ovarian platinum-resistant pembro). Mature OS data at SGO 2026 closed the loop on this SOC shift.
- Cooperative-group multi-region sponsorship. ROSELLA alone has five cooperative-group sponsors (GOG / ENGOT / APGOT / LACOG / ANZGOG). This authorship density is a unique gyn-onc structural feature versus other oncology subspecialties.
- Biomarker-defined subgroups dominate. dMMR/MSI-H, FRα+, BRCA, HRD, KRAS-mut LGSOC, B7-H4+, CDH6+, PD-L1+, p53-abn, POLE-mut — every Phase 3 in 2026 reports a molecular subgroup. The "all-comer" gyn-onc trial era is over.
- China-origin assets surface. IBI130 (Innovent anti-TROP2), BNT-324 (BioNTech B7-H3 — Mainz/Berlin biotech), and the AZ / Daiichi global ADCs all cross-list with US trade-press. Echo of the JPM 2026 "China is the story" thread.
- Surgical innovation gets a Plenary. SGO's preservation of a dedicated surgical-innovation Plenary distinguishes it from ASCO/ESMO; sentinel-node, robotic, and fertility-sparing data here often inform NCCN surgical guidelines directly.